Vantaggi
- absolutely fantastic small molecule research team in Mechelen (BE) with a strong portfolio built in record time - (Mechelen, Leiden) very collaborative mindset and running the extra miles for patients - cell therapy is a very promising field for cancer treatments. The Galapagos 7-day vein to vein treatment holds promise for many cancer patients who currently have no alternative options. Therapy has shown to be succesful in clinical trials.
Svantaggi
- acquisition and integration of the new cell therapy area in 2022 has been a difficult process, More significant organizational changes are likely in coming years. - consecutive rounds of restructuring and layoffs made it difficult to plan for the future and had impact on morale - Despite a strong portfolio, the last round of layoffs (2025, 300 people) likely impacts the full research department in Mechelen (BE) and ends all small molecule research at Galapagos, - in the new 'cell therapy' Galapagos (2025) there is still quite some uncertainty towards the future in terms of organization